2018
The changing face of adult posttransplant lymphoproliferative disorder: Changes in histology between 1999 and 2013
Tsai DE, Bagley S, Reshef R, Shaked A, Bloom RD, Ahya V, Goldberg L, Chung A, Debonera F, Schuster SJ, Huntington SF. The changing face of adult posttransplant lymphoproliferative disorder: Changes in histology between 1999 and 2013. American Journal Of Hematology 2018, 93: 874-881. PMID: 29659047, DOI: 10.1002/ajh.25116.Peer-Reviewed Original ResearchConceptsPosttransplant lymphoproliferative disorderEBV serostatusMonomorphic histologyPTLD casesLymphoproliferative disordersMonomorphic posttransplant lymphoproliferative disorderPolymorphic posttransplant lymphoproliferative disordersTime of transplantTacrolimus useImmunosuppressive regimensImmunosuppressive therapyTransplant patientsTransplant recipientsClinical managementDifferent prognosisOPTN databaseOrgan transplantationDifferent malignanciesHistologyLate occurrenceSerostatusTransplantPotential causesTherapyDisorders
2013
Chemoimmunotherapy and Withdrawal of Immunosupression for Monomorphic Posttransplant Lymphoproliferative Disorders
Podoltsev N, Zhang B, Yao X, Bustillo I, Deng Y, Cooper DL. Chemoimmunotherapy and Withdrawal of Immunosupression for Monomorphic Posttransplant Lymphoproliferative Disorders. Clinical Lymphoma Myeloma & Leukemia 2013, 13: 716-720. PMID: 24035715, PMCID: PMC3846604, DOI: 10.1016/j.clml.2013.07.006.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDoxorubicinFemaleGraft RejectionHumansImmunosuppression TherapyImmunotherapyLymphoproliferative DisordersMaleMiddle AgedOrgan TransplantationPrednisoneRituximabTreatment OutcomeVincristineWithholding TreatmentYoung AdultConceptsReduction of immunosuppressionMonomorphic PTLDMedian progression-free survivalMonomorphic posttransplant lymphoproliferative disorderGraft rejection ratePosttransplant lymphoproliferative disorderTreatment-related mortalityProgression-free survivalMulti-institutional settingGraft lossMedian OSComplete responseLymphoproliferative disordersCurrent guidelinesDisease progressionAggressive typePatientsChemoimmunotherapyPTLDComplete withdrawalImmunosuppressionCombination programStepwise approachWithdrawalExcellent results
2010
Bone marrow involvement in patients with posttransplant lymphoproliferative disorders: incidence and prognostic factors
Montanari F, O'Connor OA, Savage DG, Zain JM, Venkatraman S, McCormick EK, Crook MT, Tsao L, Sevilla DW, Bhagat G, Alobeid B. Bone marrow involvement in patients with posttransplant lymphoproliferative disorders: incidence and prognostic factors. Human Pathology 2010, 41: 1150-1158. PMID: 20381113, DOI: 10.1016/j.humpath.2009.11.016.Peer-Reviewed Original ResearchConceptsMonomorphic posttransplant lymphoproliferative disorderPosttransplant lymphoproliferative disorderBone marrow involvementPolymorphic posttransplant lymphoproliferative disordersDiffuse large B-cell lymphomaLarge B-cell lymphomaMarrow involvementLymphoproliferative disordersB-cell lymphomaSerologic parametersEpstein-Barr virus statusPosttransplant lymphoproliferative disorder patientsDe novo diffuse large B-cell lymphomaNovo diffuse large B-cell lymphomaBone marrow examinationElevated lactate dehydrogenaseBone marrow biopsyHodgkin lymphoma typeDiffuse large B-cell lymphoma casesLarge B-cell lymphoma casesB-cell lymphoma casesSensitive screening toolStaging biopsiesExtranodal involvementMarrow examination
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply